# US 11,077,125 B2 · Ophthalmic composition containing sulfasalazine and hyaluronic acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,125 B2
- Document ID: US11077125B2
- Status: Granted
- Kind: B2
- Application number: 16/469,969
- Filed: 2017-12-15
- Published: 2020-03-12
- Granted: 2021-08-03
- Earliest claimed: 2016-12-16
- Assignees: Kukje Pharma Co., Ltd.
- Applicants: Kukje Pharma Co., Ltd.
- Inventors: Hyun Ju Bae; Seung Ki Kim; Beom Jung Kim; Ju Hee Lee; Young Gwan Kim
- Web page: https://patentgrep.com/patent/US11077125B2

## CPC

- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/728: Hyaluronic acid
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 27/02: Ophthalmic agents
- A61P 27/04: Artificial tears; Irrigation solutions
- A61P 27/12: for cataracts
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An ophthalmic composition containing sulfasalazine and hyaluronic acid is disclosed.

## Claims

### Claim 1

An ophthalmic composition comprising, in an aqueous medium: sulfasalazine or its salt and hyaluronic acid or its salt as an active ingredient; and polyoxyl 40 stearate as a solubilizing agent,
wherein the polyoxyl 40 stearate is contained in an amount of 0.01 to 2 wt % based on the total weight of the composition, and
wherein the aqueous medium is phosphate buffer or citrate buffer.

### Claim 2 (depends on 1)

The ophthalmic composition of claim 1, wherein the polyoxyl 40 stearate is contained in an amount of 0.2 to 0.6 wt % based on the total weight of the composition.

### Claim 3 (depends on 1)

The ophthalmic composition of claim 1, wherein the composition further comprises a stabilizing agent.

### Claim 4 (depends on 3)

The ophthalmic composition of claim 3, wherein the stabilizing agent is selected from the group consisting of EDTA, beta-dextrin or its derivative, PVA (polyvinyl alcohol), alginic acid, PEG400, and hypromellose.

### Claim 5 (depends on 4)

The ophthalmic composition of claim 4, wherein the composition does not contain PVP and TPGS.